05858368 is referenced by 85 patents and cites 6 patents.

A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HAO), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The recombinant vaccine can be developed from primary sources of influenza, for example, nasal secretions from infected individuals, rather than from virus adapted to and cultured in chicken eggs. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. In the preferred embodiment, the cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide.

Title
Vaccine comprising a baculovirus produced influenza hemagglutinin protein fused to a second protein
Application Number
120607
Publication Number
5858368
Application Date
May 30, 1995
Publication Date
January 12, 1999
Inventor
Craig S Hackett
Wallingford
CT, US
Andrei I Voznesensky
West Hartford
CT, US
Bethanie E Wilkinson
Middletown
CT, US
Franklin Volvovitz
New Haven
CT, US
Gale E Smith
Middlefield
CT, US
Agent
Frommer Lawrence & Haug
Agent
Thomas J Kowalski
Assignee
Protein Sciences Corporation
CT, US
IPC
C12N 15/44
C07K 14/11
A61K 39/295
A61K 39/145
View Original Source